Leslie A Morrison

List of Publications by Year
in descending order

45 papers	3,493 citations	279487 23 h-index	253896 43 g-index
46 all docs	46 docs citations	46 times ranked	3985 citing authors

#	Article	IF	Citations
1	Consensus Statement for Standard of Care in Spinal Muscular Atrophy. Journal of Child Neurology, 2007, 22, 1027-1049.	0.7	754
2	Use of tissue water as a concentration reference for proton spectroscopic imaging. Magnetic Resonance in Medicine, 2006, 55, 1219-1226.	1.9	430
3	Synopsis of Guidelines for the Clinical Management of Cerebral Cavernous Malformations: Consensus Recommendations Based on Systematic Literature Review by the Angioma Alliance Scientific Advisory Board Clinical Experts Panel. Neurosurgery, 2017, 80, 665-680.	0.6	334
4	A Founder Mutation as a Cause of Cerebral Cavernous Malformation in Hispanic Americans. New England Journal of Medicine, 1996, 334, 946-951.	13.9	257
5	Endothelial TLR4 and the microbiome drive cerebral cavernous malformations. Nature, 2017, 545, 305-310.	13.7	247
6	Hemorrhage From Cavernous Malformations of the Brain. Stroke, 2008, 39, 3222-3230.	1.0	230
7	Consensus Statement on Standard of Care for Congenital Myopathies. Journal of Child Neurology, 2012, 27, 363-382.	0.7	147
8	A Locus for Cerebral Cavernous Malformations Maps to Chromosome 7q in Two Families. Genomics, 1995, 28, 311-314.	1.3	110
9	Familial Cerebral Cavernous Malformations. Stroke, 2019, 50, 1294-1301.	1.0	92
10	Evidence-based guideline summary: Evaluation, diagnosis, and management of congenital muscular dystrophy. Neurology, 2015, 84, 1369-1378.	1.5	88
11	ATP1A3 mutations in infants: a new rapidâ€onset dystoniaâ€“Parkinsonism phenotype characterized by motor delay and ataxia. Developmental Medicine and Child Neurology, 2012, 54, 1065-1067.	1.1	78
12	Atorvastatin Treatment of Cavernous Angiomas with Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial. Neurosurgery, 2019, 85, 843-853.	0.6	58
13	Polymorphisms in Inflammatory and Immune Response Genes Associated with Cerebral Cavernous Malformation Type 1 Severity. Cerebrovascular Diseases, 2014, 38, 433-440.	0.8	57
14	Developing standardized corticosteroid treatment for Duchenne muscular dystrophy. Contemporary Clinical Trials, 2017, 58, 34-39.	0.8	56
15	Distinct cellular roles for PDCD10 define a gut-brain axis in cerebral cavernous malformation. Science Translational Medicine, 2019, 11, .	5.8	51
16	Cytochrome P450 and matrix metalloproteinase genetic modifiers of disease severity in Cerebral Cavernous Malformation type 1. Free Radical Biology and Medicine, 2016, 92, 100-109.	1.3	47
17	Effect of Different Corticosteroid Dosing Regimens on Clinical Outcomes in Boys With Duchenne Muscular Dystrophy. JAMA - Journal of the American Medical Association, 2022, 327, 1456.	3.8	43
18	Association of Cardiovascular Risk Factors with Disease Severity in Cerebral Cavernous Malformation Type 1 Subjects with the Common Hispanic Mutation. Cerebrovascular Diseases, 2014, 37, 57-63.	0.8	38

#	Article	IF	Citations
19	Emerging Pharmacologic Targets in Cerebral Cavernous Malformation and Potential Strategies to Alter the Natural History of a Difficult Disease. JAMA Neurology, 2019, 76, 492.	4.5	36
20	Trial Readiness in Cavernous Angiomas With Symptomatic Hemorrhage (CASH). Neurosurgery, 2019, 84, 954-964.	0.6	34
21	Swallow Characteristics in Patients With Oculopharyngeal Muscular Dystrophy. Journal of Speech, Language, and Hearing Research, 2010, 53, 1567-1578.	0.7	32
22	Muscle Weakness and Speech in Oculopharyngeal Muscular Dystrophy. Journal of Speech, Language, and Hearing Research, 2015, 58, 1-12.	0.7	32
23	Dynamic Contrast-Enhanced MRI Evaluation of Cerebral Cavernous Malformations. Translational Stroke Research, 2013, 4, 500-506.	2.3	28
24	Permissive microbiome characterizes human subjects with a neurovascular disease cavernous angioma. Nature Communications, 2020, 11, 2659.	5.8	27
25	Brain Vascular Malformation Consortium: Overview, Progress and Future Directions. The Journal of Rare Disorders, 2013, 1, 5.	1.5	21
26	Primary bilateral silicone frontalis suspension for good levator function ptosis in oculopharyngeal muscular dystrophy. British Journal of Ophthalmology, 2012, 96, 841-845.	2.1	18
27	Effect of Simvastatin on Permeability in Cerebral Cavernous Malformation Type 1 Patients: Results from a Pilot Small Randomized Controlled Clinical Trial. Translational Stroke Research, 2020, 11, 319-321.	2.3	18
28	Dystrophinopathies. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2011, 101, 11-39.	1.0	17
29	Clinical Characterization and Blepharoptosis Surgery Outcomes in Hispanic New Mexicans With Oculopharyngeal Muscular Dystrophy. Ophthalmic Plastic and Reconstructive Surgery, 2009, 25, 103-108.	0.4	13
30	Sensitivity of patients with familial cerebral cavernous malformations to therapeutic radiation. Journal of Medical Imaging and Radiation Oncology, 2015, 59, 134-136.	0.9	13
31	Hip flexion weakness is associated with impaired mobility in oculopharyngeal muscular dystrophy: A retrospective study with implications for trial design. Neuromuscular Disorders, 2015, 25, 238-246.	0.3	12
32	High Prevalence of Spinal Cord Cavernous Malformations in the Familial Cerebral Cavernous Malformations Type 1 Cohort. American Journal of Neuroradiology, 2020, 41, 1126-1130.	1.2	12
33	Cutaneous findings of familial cerebral cavernous malformation syndrome due to the common Hispanic mutation. American Journal of Medical Genetics, Part A, 2020, 182, 1066-1072.	0.7	9
34	Automated algorithm for counting microbleeds in patients with familial cerebral cavernous malformations. Neuroradiology, 2017, 59, 685-690.	1.1	8
35	Familial Cerebral Cavernous Malformations Are Associated with Adrenal Calcifications on CT Scans: An Imaging Biomarker for a Hereditary Cerebrovascular Condition. Radiology, 2017, 284, 443-450.	3.6	8
36	Vertebral Intraosseous Vascular Malformations in a Familial Cerebral Cavernous Malformation Population: Prevalence, Histologic Features, and Associations With CNS Disease. American Journal of Roentgenology, 2020, 214, 428-436.	1.0	7

#	Article	IF	Citations
37	Seizure Incidence Rates in Children and Adults With Familial Cerebral Cavernous Malformations. Neurology, 2021, 97, e1210-e1216.	1.5	7
38	Systemic and CNS manifestations of inherited cerebrovascular malformations. Clinical Imaging, 2021, 75, 55-66.	0.8	6
39	Factors Affecting Eyelid Crease Formation Before and After Silicone Frontalis Suspension for Adult-Onset Myogenic Ptosis. Ophthalmic Plastic and Reconstructive Surgery, 2015, 31, 227-232.	0.4	5
40	Unraveling RYR1 mutations and muscle biopsies. Neurology, 2008, 70, 99-100.	1.5	4
41	Health related quality of life in young, steroid-naÃ¯ve boys with Duchenne muscular dystrophy. Neuromuscular Disorders, 2021, 31, 1161-1168.	0.3	4
42	Evidence-based guideline summary: Evaluation, diagnosis, and management of congenital muscular dystrophy: Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Issues Review Panel of the American Association of Neuromuscular & Electrodiagnostic Medicine. Neurology, 2015, 85, 1432-1433.	1.5	3
43	Assessing the association of common genetic variants in EPHB4 and RASA1 with phenotype severity in familial cerebral cavernous malformation. Molecular Genetics & Genomic Medicine, 2021, 9, e1794.	0.6	2
44	Familial cavernous malformations: a historical survey. , 0, , 15-20.		0
45	Subjective Cognitive Concerns and Attitudes toward Genetic Testing Are Associated with Depressive Symptoms and Quality of Life after Genetic Testing for the Cerebral Cavernous Malformation Common Hispanic Mutation (CCM1). Journal of Behavioral and Brain Science, 2020, 10, 118-127.	0.2	0